A New Era in MASH Treatment

In the third episode of "Liver Health Shaper," join host Jo Massoels, Chief Marketing Officer at Echosens, as we explore the pivotal role FibroScan® plays in the evolving landscape of liver health management. With the recent FDA approval of Rezdiffra™, the groundbreaking new treatment for MASH patients with moderate to advanced fibrosis, accurate, non-invasive diagnostics have never been more essential. Our distinguished guests, Dr. Naim Alkhouri, Chief Medical Officer at Arizona Liver Health, and Dr. Mazen Noureddin, Professor of Medicine and Director of the Houston Research Institute, discuss the new treatment and share their expert insights on how FibroScan®, equipped with advanced Guided VCTE™ technology, is transforming the way clinicians diagnose, monitor, and manage liver disease. They discuss the crucial role FibroScan® plays in identifying the right candidates for Rezdiffra™, as well as the role it plays in streamlining the prior authorization process.   Listeners will also learn how digital connectivity between FibroScan® and the Liver Health Management platform enhances clinical decision-making and improves patient care, making the future of liver health more accessible and efficient for both physicians and patients. Guests:Dr. Naim Alkhouri, Chief Medical Officer at Arizona Liver HealthDr. Mazen Noureddin, Professor of Medicine and Director of the Houston Research Institute Topics covered in the episode:The evolving role of FibroScan® in diagnosing and managing liver disease in light of a new, groundbreaking treatmentHow to navigate the prior authorization process for Rezdiffra™How Guided VCTE™ technology improves diagnostic precision and workflow efficiencyThe integration of FibroScan® with the Liver Health Management platform for better patient monitoringThe future of liver health management with non-invasive diagnostics at the forefrontHosted on Ausha. See ausha.co/privacy-policy for more information.